

Lung cancer Part 2 - Reference list

1. Cancer Council Australia Lung Cancer Guidelines Working Party. Clinical practice guidelines for the treatment of lung cancer. 2017. Sydney: Cancer Council Australia. Available from: https://wiki.cancer.org.au/australia/Guidelines:Lung_cancer.
2. Ball, D., Personal communication. 2014.
3. Bankhead, C. AACR: biomarkers predict best lung cancer therapy. Medpage Today 2010 17.03.2011]; Available from: www.medpagetoday.com/MeetingCoverage/AACR/19616.
4. White, S. and N. Pavlakis, Evolution of biological therapies in the management of non-small cell lung cancer. *Cancer Forum*, 2008. 32(3): p. 147-150.
5. Cooper, W.A. and S.A. O'Toole, Molecular pathology in lung cancer. *Cancer Forum*, 2013. 37(2).
6. Mohan, K.N. and Chaillet, J.R., 2013. Cell and molecular biology of DNA methyltransferase 1. In *International review of cell and molecular biology* (Vol. 306, pp. 1-42). Academic Press.
7. Global Oncology Trends 2018: Innovation, Expansion and Disruption Institute Report - May 24, 2018 <https://www.iqvia.com/institute/reports/global-oncology-trends-2018#reportcharts>
8. Gower, A., Wang, Y. and Giaccone, G., 2014. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. *Journal of molecular medicine*, 92(7), pp.697-707.
9. Reck, M., Mok, T.S., Nishio, M., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D. and Thomas, C.A., 2019. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *The Lancet Respiratory Medicine*, 7(5), pp.387-401.
10. Cancer Council Australia. Optimal care pathway for people with lung cancer. Sydney: Cancer Council Australia. 2016; Available from: https://www.cancer.org.au/content/ocp/health/optimal-care-pathway-for-people-with-lung-cancer-june-2016.pdf#_ga=2.174241698.1655854395.1565563202-215653191.1536909745
11. Vinod, S.K. and D.L. Ball, Radiotherapy in lung cancer. *Cancer Forum*, 2013. 37(2).
12. Walters, S., Maringe, C., Coleman, M.P., Peake, M.D., Butler, J., Young, N., Bergström, S., Hanna, L., Jakobsen, E., Kölbek, K. and Sundstrøm, S., 2013. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. *Thorax*, 68(6), pp.551-564.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. Version 2.2014. 2014; Available from: http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
14. Slotman, B., et al., Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. *New England Journal of Medicine*, 2007. 357(7): p. 664-672.
15. Ferraro, D. and M. Millward, Small cell lung cancer update. *Cancer Forum*, 2013. 37(2).
16. Pijls-Johannesma, M., D. De Ruysscher, J. Vansteenkiste, A. Kester, I. Rutten and P. Lambin (2007). "Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials." *Cancer Treat Rev* 33(5): 461-473.
17. Flannery, M., Nursing management of the client with lung cancer, in *Core curriculum for oncology nursing*, 4th Edition, J. Itano and K. Taoka, Editors. 2005, Elsevier: St Louis